Pain Is the Parent of all Progress – The Case for Contrarians: Why the Low Momentum Anomaly Represents Active Management’s Greatest Opportunity in Nearly a Decade
Introduction: Is a Preponderance of Underperformers a Problem? Momentum ....
Value & Momentum Drawdowns – The Slow Bleed vs. The High Speed
Introduction: The vicissitudes and vagaries of value and momentum strategies; evaluating when strategies underperform Drawdowns: Value drawdowns are slow with violent snap-backs; momentum declines are rapid with slow recoveries ...
The Revenue Wreck – Are We Paying Rational Prices for an Ex-Growth America?
Introduction: R1000 Sales Growth Is Approaching Great Recession Lows Valuations Have Not Fallen to Reflect Slowing Sales Growth Kailash Portfolio by Growth Quintile: Best Opportunity in Fastest Growing Kailash ...
Batter Up! More from Our Core: Revisiting Fundamental Favorites for Large Cap
Introduction Our Fundamental Favorites and the Three Pillars Fundamental Scarcity Fundamental Favorites’ Characteristics Drivers of Greater Excess Returns Conclusions: A Small but Privileged Pond Introduction A year ago, we ...
A Rare Opportunity in Top Shareholder Yields
Introduction Top Shareholder Yield Stocks Have Significantly Underperformed TSY Stocks Outperformed Significantly When Their Index Weights Fell to Levels Similar to Current Levels Top Shareholder ...
Politicians and Corporate Stock Repurchases – Getting the Facts Straight in This Politicized Issue
Introduction Large Stock Repurchases Are Not Being Funded by Debt Repurchasers Are Not Starving Their Companies of Investment Smaller Companies Have Some Different Dynamics, but These Differences Are Inconsequential ...
Are We Being Served a Fat Pitch in S&P500 IT?
Executive Summary Introduction: The recent reversal in Value vs. Growth stock performance since our August 2015 paper was reminiscent of the strong IT stock price movements seen during the time ...
Where Are We in the Biotech Cycle?
Introduction Biotech M&A Cycle Biotech IPO Cycle Does Valuation Matter Within Biotech? Conclusion: At Least Society (If Not Investors) Will Benefit from Biotech Investment Introduction News about Abbvie’s acquisition ...
Update on Comparing SMID Valuation Tails
Executive Summary Introduction: In May 2014 we published the white papers “Bubble Trouble? Comparing the Current Markets to 1999 and 2007” and “Comparing the Small & Mid Cap Valuation ...
Introducing the Kailash Large Cap Rankings Tool
Introduction Features Differences from Other Kailash products Performance Conclusions Exhibits Appendix: User’s Manual for the Kailash Interactive Rankings Tool Introduction We are pleased to introduce the new Kailash Capital Research, LLC ...
Batter Up! More from Our Core
Executive Summary Introduction: We believe it is fitting for us to focus on our commitment to adding value to clients’ processes in a manner that respects your time. While ...
How Likely Is a 25-Bagger within 10 Years? We Are No Fans of, at Best, 4% Odds
We would like to start with a pre-emptive apology for being terribly boring folks who tend to be grounded in probabilities. That predisposition has made the current environment somewhat ...